Aptose Biosciences announced the closing of the acquisition by Hanmi Pharmaceutical, delisting shares on July 3. Shareholders received C$2.41 per share, representing a 28% premium over the prior 30-day VWAP.
Aptose Biosciences announced the closing of the acquisition by Hanmi Pharmaceutical, delisting shares on July 3. Shareholders received C$2.41 per share, representing a 28% premium over the prior 30-day VWAP.